Defects in tumor cell immunogenicity: Lymphokine signals in in vitro cytolytic responses to tumor alloantigens

Ashley, Michael P.; Kotlarski, Ieva; Vari, Frank

doi:10.1016/0008-8749(87)90158-4

Cited by 3 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar result was obtained with B16 melanoma by Ashley et al (21) although not by Heath and Boyle (19). Whether these results can be attributed to IL2 in the lymphokine preparation, however, is uncertain, as crude supernatants of Concanavalin-A-stimulated spleen cells were used in all cases.…”

Section: Why Are Some Tumours Poorly Immunogenic?supporting

confidence: 87%

“…However, MC2 was immunogenic in vivo and so the significance of this finding is unclear. In contrast, indomethacin had no effect on the inability of B16 to induce a cytotoxic response in vitro (21).…”

Section: Why Are Some Tumours Poorly Immunogenic?mentioning

confidence: 74%

“…In another system we have shown that some leukaemic cell lines require relatively large numbers of accessory cells (monocytes; approximately 10%) in the responding peripheral blood lymphocyte population for allostimulation to occur (22). In addition to being poorly immunogenic, B16 cells were somewhat refractory to lysis in vitro (19; 21), although they were lysed on prolonged incubation (21) and, clearly, could be lysed by a strong anti-H-2'' response in vivo.…”

Section: Tumour Immunogenicity In Allogeneic Systemsmentioning

confidence: 99%

“…Prostaglandin production by tumour cells may also be immunosuppressive. Ashley et al (21) demonstrated that MC2 sarcoma cells elicited a cytotoxic response in vitro only if indo-methacin, an inhibitor of prostaglandin synthesis, was included in the cultures. However, MC2 was immunogenic in vivo and so the significance of this finding is unclear.…”

Section: Why Are Some Tumours Poorly Immunogenic?mentioning

confidence: 99%

See 3 more Smart Citations

The immunogenicity of tumour cells

Ashman

1987

Immunol Cell Biol

View full text Add to dashboard Cite

Summary Immunological mechanisms are demonstrably of central importance in preventing the development of certain virus‐associated cancers in animals and man; however, they do not appear to fulfil this role in the majority of ‘spontaneous’ tumours. This does not, however, necessarily indicate that spontaneous tumours lack potential target antigens for immunologically mediated destruction. Work in the field of transplantation immunology has clearly shown that certain cell types fail to elicit rejection reactions despite their possession of alloantigens. Similarly, some tumour cell types are poorly immunogenic to the point that they can grow in and kill animals despite a major histocompatability barrier. These tumours are, however, susceptible to destruction in vivo in appropriately allo‐sensitized animals. Thus, some tumours may be able to grow in autologous or syngeneic hosts because of their poor immunogenicity, despite the fact that they express potential (tumour‐associated) rejection antigens. It may be possible to manipulate this situation for therapeutic purposes.

show abstract

Section: Why Are Some Tumours Poorly Immunogenic?supporting

confidence: 87%

Section: Why Are Some Tumours Poorly Immunogenic?mentioning

confidence: 74%

Section: Tumour Immunogenicity In Allogeneic Systemsmentioning

confidence: 99%

Section: Why Are Some Tumours Poorly Immunogenic?mentioning

confidence: 99%

See 2 more Smart Citations

The immunogenicity of tumour cells

Ashman

1987

Immunol Cell Biol

View full text Add to dashboard Cite

show abstract

“…However, it expresses sufficient MHC antigens to be lysed in vivo (4) and in vitro (5), provided that the response is either aided by lymphokine or induced by other cells carrying H-2*' antigens.…”

Section: Introductionmentioning

confidence: 99%

In vivo H‐2K and H‐2D antigen expression In two allogeneic mouse tumours of low immunogenicity

Ashley

Kotlarski

1987

Immunol Cell Biol

Self Cite

View full text Add to dashboard Cite

Summary The B16 melanoma of C57BL/6 mice immunizes very poorly, even against its own major histocompatibility complex (MHC) antigens. B16 cells expressed both H‐2K and H‐2D antigens in vitro as judged by binding of monoclonal antibodies to these antigens in indirect immunofluorescence staining. The in vivo MHC antigen expression of B16 was examined and compared with that of a second C57BL/6 tumour, the Lewis lung carcinoma (3LL). whose defective immunogenicity has been attributed to a selective deficiency‐ in H‐2K antigen expression. We found that 125I‐labeiled cells of both tumours expressed sufficient allo‐antigen in vivo to be lysed in BALB/c mice which had been pre‐immunized with C57BL/6 lymphoid cells. 125I‐B16 cells were also lysed in MHC‐recombinant mice which had been immunized against either H‐2Kb or H‐2Db, indicating that B16 cells express both of these MHC antigens in vivo. This contrasted with our findings with 125I‐3LL cells which were destroyed in mice immunized against H‐2Db but not in those immunized against H‐2Kb. Thus, B16 illustrates a different deficiency in tumour cell immunogenicity which appears not to be attributable to an absence of either of the class 1 MHC antigens.

show abstract